Skip to content
ATLAS PREP HQ
Healing

Ara-290

Cibinetide / ARA-290, an 11-amino-acid helix-B surface peptide derived from erythropoietin

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Limited Human Evidence

Route

Subcutaneous in human cibinetide trials and the community reference.

Common format

16 mg vial

Research focus

small-fiber neuropathy

Evidence level

Limited Human Evidence

Typical cycle

4–8 weeks

Healing research motifHealing

Ara-290 in 30 seconds

Atlas Fast Read

What it is

Cibinetide / ARA-290, an 11-amino-acid helix-B surface peptide derived from erythropoietin

Why people care

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Human evidence

Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

Biggest misconception

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Bottom line

Ara-290 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.

Overview

What is Ara-290?

Ara-290 is cibinetide / ARA-290, an 11-amino-acid helix-B surface peptide derived from erythropoietin. Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Designed from the helix-B surface of erythropoietin to preserve tissue-protective signaling without stimulating red-blood-cell production. It was later developed clinically under the name cibinetide for small-fiber neuropathy and inflammatory disorders.

Mechanism

How it works

Selectively activates the innate repair receptor formed by EPOR and CD131 rather than the classical erythropoietic EPO receptor. Downstream signaling reduces inflammatory injury and supports tissue repair without increasing red-cell production.

Research areas

small-fiber neuropathyinflammationtissue protectionsarcoidosis-related neuropathy

Evidence

What does the evidence actually say?

Limited Human Evidence

Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

Cibinetide/ARA-290 has been tested in small human studies, including patients with sarcoidosis-associated small-fiber neuropathy and metabolic neuropathy. Some trials reported improvements in symptoms or nerve-fiber measures, but sample sizes were small and confirmatory phase 3 evidence is lacking.

Preclinical evidence

Animal models show anti-inflammatory, tissue-protective, neuropathy, renal, and wound-related effects through the innate repair receptor. This mechanistic body of work is broader than the current human clinical evidence.

Knowledge gaps

Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Clinical research commonly used 4 mg/day; Community references 2 mg/day for week 1 then 4 mg/day.

Frequency

Once daily.

Timing

No established time-of-day requirement.

Route

Subcutaneous in human cibinetide trials and the community reference.

Cycle length

4–8 weeks

Reconstitution

Community reference: 1.6 mL bacteriostatic water per 16 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized refrigerated/frozen; reconstituted 2–8 °C for up to 28 days.

Monitoring

For neuropathy research: symptom scores and neurologic testing are more relevant than routine labs; CBC, CMP, glucose/HbA1c and inflammatory markers may provide context.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Small human cibinetide studies generally reported tolerability, with possible headache, nausea, injection-site reactions or transient symptoms. Unlike erythropoietin, it is designed not to increase hematocrit.

Contraindications

No approved broad contraindication profile exists. Pregnancy/breastfeeding, serious systemic illness and hypersensitivity require exclusion or specialist oversight in research settings.

Interactions

Formal drug-interaction data are limited. Concurrent immunomodulatory or neuropathic-pain therapy can confound outcome assessment.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Ara-290 has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.

More in Healing

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide

Healing

Cartalax

Short peptide bioregulator studied for connective-tissue support and fibroblast-related activity.

Read guide